Summary
BlinkLab Limited (BB1) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BlinkLab Limited ever had a stock split?
BlinkLab Limited Profile
| Technology Hardware, Storage & Peripherals Industry | Information Technology Sector | Dr. Hendrikus Johannes Boele M.D., Ph.D. CEO | ASX Exchange | AU0000322851 ISIN |
| AU Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BlinkLab Limited, established in 2021 and headquartered in Sydney, Australia, is a vanguard in the domain of neurobehavioral testing using smartphone technology. This innovative company dedicates itself to the development and commercialization of intellectual property focused on crafting a bridge between advanced technology and neurological healthcare. Through its pioneering efforts, BlinkLab transcends traditional barriers in neurometric testing, offering accessible, efficient, and reliable solutions for diagnosing a spectrum of neurological and psychiatric disorders.
Products and Services
BlinkLab Limited has introduced a groundbreaking smartphone-based application, acting as a portable medical device to conduct sophisticated neurometric tests. These tools are crucial for the early detection and management of various neurodevelopmental conditions.
- Eyeblink Conditioning Test
- Prepulse Inhibition of Acoustic Startle
- Habituation of Eye Blink Response
This test evaluates the subject's learning and memory capabilities by measuring their conditioned response to stimuli. It's a critical tool in assessing cognitive function and has been adapted to identify early signs of neurological disorders through the ease and accessibility of a smartphone interface.
An innovative adaptation of a classic neurobehavioral test, this application measures the reduction of the startle reflex when a weaker prepulse precedes a strong sensory stimulus. This test is instrumental in diagnosing psychiatric and neurological conditions by analyzing the brain's filtering process, crucial for identifying anomalies associated with disorders like schizophrenia.
Focusing on the basic neural mechanism of learning and memory, this test observes the frequency and intensity of a subject's blink response to repetitive stimuli. The application's ability to quantify habituation rates is valuable for diagnosing and understanding the progression of neurological and psychiatric disorders, including autism and ADHD.
The application’s functionality extends beyond test administration, equipped with a sophisticated backend system. This system records, uploads, and analyzes the neurometric test results. Leveraging machine learning algorithms, the platform provides advanced diagnostic support, enhancing the accuracy and reliability of identifying ASD, ADHD, schizophrenia, and other neurodevelopmental conditions.
